Development of novel tools for the in vitro investigation of drug-induced liver injury

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

Introduction: Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification. Since species-specific differences in metabolism and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans.Areas covered: Over the last few decades, numerous in vitro models have been developed to replace animal testing. The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed. Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction. This review presents an overview of the currently used alternative toxicological models and of the most advanced approaches in the field of DILI research.Expert opinion: It seems unlikely that a...
Original languageEnglish
Pages (from-to)1523-1537
Number of pages15
JournalExpert Opinion on Drug Metabolism & Toxicology
Volume11
Issue number10
DOIs
Publication statusPublished - 3 Oct 2015

Keywords

  • -omics technologies
  • 3D culture
  • drug-induced liver injury
  • multicellular hepatospheres
  • primary hepatocytes
  • sequencing technologies
  • toxicogenomics

Cite this

@article{00fa18446a0e4b5cb181c1936dfc8e54,
title = "Development of novel tools for the in vitro investigation of drug-induced liver injury",
abstract = "Introduction: Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification. Since species-specific differences in metabolism and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans.Areas covered: Over the last few decades, numerous in vitro models have been developed to replace animal testing. The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed. Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction. This review presents an overview of the currently used alternative toxicological models and of the most advanced approaches in the field of DILI research.Expert opinion: It seems unlikely that a...",
keywords = "-omics technologies, 3D culture, drug-induced liver injury, multicellular hepatospheres, primary hepatocytes, sequencing technologies, toxicogenomics",
author = "Jian Jiang and Wolters, {Jarno EJ} and {van Breda}, {Simone G} and Kleinjans, {Jos C} and {de Kok}, {Theo M}",
year = "2015",
month = "10",
day = "3",
doi = "10.1517/17425255.2015.1065814",
language = "English",
volume = "11",
pages = "1523--1537",
journal = "Expert Opinion on Drug Metabolism & Toxicology",
issn = "1742-5255",
publisher = "Routledge/Taylor & Francis Group",
number = "10",

}

Development of novel tools for the in vitro investigation of drug-induced liver injury. / Jiang, Jian; Wolters, Jarno EJ; van Breda, Simone G; Kleinjans, Jos C; de Kok, Theo M.

In: Expert Opinion on Drug Metabolism & Toxicology, Vol. 11, No. 10, 03.10.2015, p. 1523-1537.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Development of novel tools for the in vitro investigation of drug-induced liver injury

AU - Jiang, Jian

AU - Wolters, Jarno EJ

AU - van Breda, Simone G

AU - Kleinjans, Jos C

AU - de Kok, Theo M

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Introduction: Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification. Since species-specific differences in metabolism and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans.Areas covered: Over the last few decades, numerous in vitro models have been developed to replace animal testing. The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed. Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction. This review presents an overview of the currently used alternative toxicological models and of the most advanced approaches in the field of DILI research.Expert opinion: It seems unlikely that a...

AB - Introduction: Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification. Since species-specific differences in metabolism and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans.Areas covered: Over the last few decades, numerous in vitro models have been developed to replace animal testing. The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed. Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction. This review presents an overview of the currently used alternative toxicological models and of the most advanced approaches in the field of DILI research.Expert opinion: It seems unlikely that a...

KW - -omics technologies

KW - 3D culture

KW - drug-induced liver injury

KW - multicellular hepatospheres

KW - primary hepatocytes

KW - sequencing technologies

KW - toxicogenomics

U2 - 10.1517/17425255.2015.1065814

DO - 10.1517/17425255.2015.1065814

M3 - Article

C2 - 26155718

VL - 11

SP - 1523

EP - 1537

JO - Expert Opinion on Drug Metabolism & Toxicology

JF - Expert Opinion on Drug Metabolism & Toxicology

SN - 1742-5255

IS - 10

ER -